

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C12Q 1/68, C12M 1/34, G01J 1/42	A1	(11) International Publication Number: WO 94/12665 (43) International Publication Date: 9 June 1994 (09.06.94)
(21) International Application Number: PCT/US93/11263 (22) International Filing Date: 23 November 1993 (23.11.93) (30) Priority Data: 07/980,283 23 November 1992 (23.11.92) US (71) Applicant: R-P TECHNOLOGIES, INC. [US/US]; P.O. Box 45285, Madison, WI 53744-5285 (US). (71)(72) Applicant and Inventor: ROYER, Catherine, A. [US/US]; 424 Hillington Way, Madison, WI 53705 (US). (74) Agents: SVENSSON, Leonard, R. et al.; Birch, Stewart, Kolasch & Birch, 8110 Gatehouse Road, Suite 500 East, P.O. Box 747, Falls Church, VA 22040-0747 (US).		(81) Designated States: JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i> <i>With amended claims.</i>
(54) Title: QUANTITATIVE DETECTION OF MACROMOLECULES WITH FLUORESCENT OLIGONUCLEOTIDES (57) Abstract A method is described by which the association between an oligonucleotide labeled by attachment of a fluorophore and another macromolecule such as a protein or nucleic acid may be determined quantitatively in solution accurately and with high sensitivity. In the performance of this method the polarization of fluorescence of an extrinsic fluorescence probe that is covalently coupled to the oligonucleotide is determined. Changes in fluorescence polarization are related directly to the degree of association between the labeled oligonucleotide and another macromolecule and may be used to quantify the association. Because of its high sensitivity and accuracy, this method may be used to make reliable quantitative measurements of very small amounts of complexes formed between labeled oligonucleotides and proteins, nucleic acids or other macromolecules. The method also allows the accurate calculation of important biochemical parameters such as dissociation constants. The method, which is rapid and solution-based, has a broad range of application in biochemistry, genetic cloning and molecular biology, as well as in clinical diagnostics.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

**QUANTITATIVE DETECTION OF MACROMOLECULES
WITH FLUORESCENT OLIGONUCLEOTIDES**

BACKGROUND OF THE INVENTION

Field of the Invention

5 The invention relates to the use of measurement of the polarization of the fluorescence emission from a labelled macromolecule in order to assess the binding of the labelled macromolecule to a second macromolecule. Thus, the invention is directed to analytic methods for
10 determining such binding in a quantitative fashion. The invention is also directed to apparatus for conducting binding analyses using measurement of fluorescence polarization.

Description of the Related Art

15 The use of labeled oligonucleotides as probes in macromolecular analysis is an important technique in molecular biology. Oligonucleotides have been labeled with radioisotopes, enzymes or fluorescent molecules. Because of the relatively low molecular weights of
20 oligonucleotides, and the common availability of instrumentation for their automated synthesis, oligonucleotides are often used in blot-hybridization procedures or in gel-retardation assays for the detection and qualitative evaluation of macromolecules
25 with which they may associate. These macromolecules may

be either proteins, RNA molecules or DNA molecules.

In a standard blot-hybridization procedure, the target macromolecule is separated by electrophoresis in a gel matrix, commonly agarose or polyacrylamide. It is then transferred to a membrane in such a way as to preserve its relative spatial positioning within the gel matrix and fix it stably to the membrane. Alternatively, the macromolecule may be attached to the membrane without prior electrophoresis. The presence of the macromolecule on the membrane is determined by binding to it a labeled oligonucleotide and subjecting the complex to autoradiography or, if the oligonucleotide is labeled with radioisotope, by scintillation counting.

In a standard gel retardation assay an oligonucleotide that has been labelled with radioisotope or other detectable moiety is electrophoresed in a gel matrix, commonly made of agarose or acrylamide, under non-denaturing conditions. The labelled oligonucleotide is also associated with a protein that may bind to the oligonucleotide and the mixture is electrophoresed on a gel, commonly in a neighboring lane, for comparing with the unassociated oligonucleotide. Because of its higher molecular weight and less negative charge, the protein will exhibit lower mobility in the gel than the unassociated oligonucleotide. If the oligonucleotide forms a stable complex with the protein, it will also exhibit a lower mobility than that of the unassociated oligonucleotide. Comparison of the mobility of the oligonucleotide in the presence and absence of the protein allows qualitative determination of whether a complex forms between the two macromolecules. These basic methods are used for a very large variety of determinations in basic genetic research, genetic engineering, the medical sciences, and agricultural testing.

The present invention relates to a method for

detecting and quantitating complexation between nucleic acids and proteins or other macromolecules which comprises the measurement of the polarization of fluorescence of an extrinsic fluorophore covalently coupled to an oligonucleotide. The oligonucleotide can be an oligodeoxyribonucleotide, an oligonribonucleotide or a co-polymer of both. The nucleotide bases can be derivatized, as can the backbone chain. The oligonucleotide can be single-, double- or triple-stranded. The length of the oligonucleotide is determined by the specific experiment being conducted, but is preferably less than 40 residues long, more preferably being less than 25 residues long and most preferably 8-10 residues long.

The fluorophore is incorporated into the oligonucleotide at any position using standard automated DNA synthesis techniques and fluorescently labeled amino-linker compounds (e.g. those available from Clontech, Inc., La Jolla, CA). Alternately, unlabeled amino-linker compounds can be incorporated and subsequently labeled with the fluorescent compound. A variety of fluorophores may be used, including fluorescein, eosin, coumarin and dansyl derivatives. The fast rotation about the short axis of the oligonucleotide results in a low value of the fluorescence polarization of the probe covalently coupled to the oligonucleotide. This value is obtained by exciting the fluorescently labeled oligonucleotide with the appropriate wavelength of plane polarized exciting light and monitoring the emission of light polarized in the planes parallel and perpendicular to the plane of polarization of the exciting light. The fluorescence polarization is calculated as:

$$p = (I_{\parallel} - I_{\perp}) / (I_{\parallel} + I_{\perp})$$

where I_{\parallel} is the intensity of the emitted light polarized in a plane parallel to the plane of polarization of the

exciting light and I_{\perp} is the intensity of the emitted light polarized in a plane perpendicular to the plane of polarization of the exciting light.

The anisotropy of the emission is

$$2/3 [1/(1/p - 1/3)]$$

This value is analogous to the polarization yet linear with respect to the total fluorescence emission intensity.

Fluorescence polarization is the basis for a series of patented assays for the clinical detection of drugs, steroids and other antigens (US Patents 4,269,511; 4,516,856; 4,585,862; 4,668,640; 4,784,961 4,902,630; 4,952,691; 5,066,426; European patent application 86102035.2). Although there are a number of variations, all of these assays rely on the observation of a large change in the fluorescence polarization of fluorescein upon changing its interaction with specific or non-specific antibodies when the drug of interest is present in the assay solution. If the presence of the drug results in the dissociation of the fluorescein-antibody complex, for example, then the fluorescence polarization will exhibit a large decrease. The sensitivity of these assays is less than 10 pM. Urios and Cittanova (15) describe the use of fluorescently labeled Fab fragments of antibodies to perform fluorescence polarization measurements. The sensitivity of their assay is 2.5 μ M. The use of a fluorescent-labeled oligonucleotide probe was reported by Murakami et al (17). Their reported sensitivity was 100 nanomolar. Giedroc et al. (16) used fluorescence anisotropy in evaluating the presence of single stranded DNA molecules. Their assays were conducted at oligonucleotide concentrations of 2 to 8 μ M.

SUMMARY OF THE INVENTION

One object of the present invention is to provide a method by which the binding of two macromolecules to each other can be detected in the solution phase by measuring the polarization of the fluorescent emission from a probe moiety. Preferably, the probe is attached to one macromolecule and binding is determined directly by an increase in the fluorescence polarization. A second object of the present invention is to provide an apparatus suitable for performing fluorescence polarization measurements with very high sensitivity so as to be able to perform such measurements quantitatively on very small samples. In preferred embodiments of the apparatus, detection of the polarization of the fluorescent emission of as little as one femtomole of fluorophore can be detected.

A third object of the present invention is to provide diagnostic methods which are based upon measuring the binding of a polynucleotide to a second polynucleotide, or alternatively to a protein, by means of quantitation of the polarization of the emission from a fluorophore covalently attached to either said polynucleotide.

BRIEF DESCRIPTION OF THE DRAWINGS

Figures 1A shows the titration of a fluorescein-labeled double-stranded oligodeoxynucleotide containing a trp operator sequence with purified tryptophan repressor protein. The buffer conditions were 10 mM phosphate, 0.1 mM EDTA, 10% glycerol, pH 7.6 in presence of 0.4 mM L-tryptophan. Total sample volume was 700 μ l. The concentration of the fluorescein-labeled oligonucleotide was 200 pM. The anisotropy of fluorescence is plotted as a function of the logarithm of the protein concentration expressed as monomer. The lines through the points represent the non-linear analysis of the data in terms of a model in which a monomer/dimer equilibrium

is coupled with the dimer-DNA binding equilibrium.

Figures 1C, 1D show the free energy diagrams for a simple binding scheme and the protein-protein and protein-DNA coupled interaction scheme. The data were
5 fit using these two models, as shown in Figures 1A and 1B.

Figure 2. Plot of X^2 (ordinate) vs. free energy in kcal (abscissa) for the thermodynamic model given in Figures 1C.

10 Figure 3 shows the dependence of the binding profile of trp repressor to a synthetic oligonucleotide containing a trp operator sequence on the concentration of the oligonucleotide. The stoichiometry of the complexes formed is a subtle function of the absolute and relative
15 concentrations of protein and oligonucleotide. Thus, a primary plateau is reached which is more apparent at low DNA concentrations, followed by a further increase in the anisotropy as higher order complexes are formed. DNA concentrations were 200 pM, 1 nM, and 20 nM.

20 Figure 4 shows the dependence of the binding of the trp repressor protein to the operator oligonucleotide upon the concentration of tryptophan. Open circles represent binding of protein to 1 nM oligonucleotide in presence of 4.0 mM tryptophan, open triangles show binding in the
25 presence of 0.4 mM tryptophan, open diamonds 40 μ M tryptophan and the closed circles denote the binding profile in absence of the tryptophan co-repressor.

Figure 5. Plan view drawing of a lamp-based, T-format high sensitivity polarization fluorometer.

30 Figure 6. Plan view drawing of a laser-based, T-format high sensitivity polarization fluorometer.

Figure 7. Plan view drawing of a lamp-based, L-format high sensitivity polarization fluorometer.

Figure 8. Plan view drawing of a laser-based, L-format high sensitivity polarization fluorometer.

- 5 Figure 9. Detail drawing in plan view of fiber optic, lamp-based, T-format high sensitivity polarization fluorometer, in particular showing detail of sample compartment and the arrangement of the film polarizers.

DETAILED DESCRIPTION OF THE INVENTION

- 10 The present invention defines methods by which the association between a fluorescently labeled oligonucleotide and another macromolecule such as a protein or a nucleic acid may be measured rapidly, accurately and with high sensitivity in solution. In
15 particular, this invention relates to the detection of complex formation (i.e., formation of a stable, specific noncovalent association) between the oligonucleotide and the target macromolecule, each at very low concentration, through the measurement of the
20 polarization of fluorescence of an extrinsic fluorescent probe covalently coupled to the oligonucleotide. The fluorescence polarization detection is based upon the increase in the rotational correlation time of the probe covalently linked to the oligonucleotide as a result of
25 the increase in the size of the tumbling particle when the protein or other macromolecule is complexed with it, compared to the rotational correlation time of the fluorescently labeled oligonucleotide in the absence of interacting macromolecules. Using the appropriate
30 instrumentation, measurements of fluorescence polarization may be made very rapidly, usually on the order or 5-10 minutes. In contrast, a blot-hybridization or gel retardation analysis, as described above, will take a full day -- and very often longer --

to complete. Alternative uses of fluorescence polarization measurements in macromolecular analysis have been described (15-17). However, these methods do not provide adequate sensitivity to make them useful in practical applications. Biological macromolecules are often found in extremely small amounts, requiring analytical sensitivities at less than nanomolar levels. The method described in the present invention allows measurements to be made at the picomolar level -- well within the range required and at least 10,000-fold more sensitive than reported elsewhere. Alternative methods of macromolecular analysis are largely qualitative and, therefore, inaccurate. The method of the present invention provides for highly accurate quantitative measurements.

High sensitivity, and thus a high signal-to-noise ratio necessary to accurate quantitative analysis of low concentrations of interacting molecules, is achieved using an ILC 300 watt Xenon arc lamp/ISA monochromator excitation source coupled to the sample compartment through an Oriel rectangular to circular fused silica fiber optic cable. Film polarizers mounted on the sample holder in a crossed T-format in emission and with parallel orientation in excitation permit detection to the 10 picomolar limit. It is expected that since fluorescence is proportional to the excitation source intensity, the use of a laser excitation source will result in a 10 to 100-fold increase in sensitivity, well into the subpicomolar range of sample concentration.

Several other embodiments of the apparatus can be used. The T-format using fixed polarizing elements as illustrated in Figures 5 and 6 can be changed to an L-format using a rotatable emission polarizer. Use of a laser illumination means eliminates the need for the excitation polarizer element (as laser light is plane polarized by its nature) and lenses for focusing the excitation light. Use of a laser tunable to several

wavelengths, for instance a dye laser, provides for an apparatus having greater flexibility in the number of compounds which can be used as fluorescent labels in the assay of the present invention.

5 A preferred embodiment of the invention is an apparatus for measuring the polarization of fluorescent emission which can be understood by referring to the drawing Figures 5 and 6 and which comprises:

A box for the exclusion of light in which is placed
10 an illumination means (1) so as to illuminate a sample chamber (7), through a collimating lens (3) and an excitation focusing lens (4) for collecting the light and focussing it upon the sample chamber, and further through a first polarizing means for plane polarizing
15 the light from said illumination means (6), said lenses and first polarizing means, being mounted in a line connecting said illumination means and said sample chamber, and further said sample chamber being mounted between two additional polarizing means (8 and 8a), said
20 polarizing means being placed so that the line between them and including said sample chamber is perpendicular to the light path from said illumination means to said sample chamber, said polarizing means being mounted so that the plane of polarization of the second of said
25 polarizing means is parallel to the plane of polarization of said first polarizing means and also so that the plane of polarization of said second polarizing means is perpendicular to the plane of polarization of the third of said polarizing means and in which box is
30 also placed detection means (12 and 12a) for the collection and quantitation of the amount of light which passes through said polarizing means from said sample chamber to said detecting means. Interposed between the emission polarizers and detection means are emission
35 filters (9, 9a) for selectively passing light of a narrow range of wavelengths from the emission polarizers to the detecting means and also emission lenses (10,

10a) for focussing light emerging from the sample chamber onto the detecting means. Shutters (11, 11a) can also be interposed between the emission lenses and detection means for controlling the entry of light into
5 the detection means and between the illumination means and the sample compartment (11b in Figure 6) to control entry of light into the sample compartment. Enclosed in a separate compartment (13) are additional components of the apparatus including motors for driving the shutters
10 and monochromator (if it is included), and electronic devices for data collection and processing.

A second preferred embodiment of the invention is an apparatus for measuring the polarization of fluorescent emission which can be understood by
15 referring to drawing Figures 7 and 8 and which comprises:

A box for the exclusion of light in which is placed an illumination means (1) so as to illuminate a sample chamber (6) through an excitation lens (3) for focussing
20 the excitation light upon the sample chamber and further through an excitation filter (4), wherein said excitation filter passes only a narrow range of wavelengths of light, and finally through a fixed means of plane polarizing light which shines on said sample
25 chamber (5), such that each of elements 3 and 4 and 5 are mounted in the light path from said illuminating means to said sample chamber, said sample chamber being mounted relative to a rotatable polarizing means (8), which plane polarizes light which passes through said
30 rotatable plane polarizing means, so that a path from said illumination means through said sample chamber to said rotatable polarizing means forms a right angle with the sample chamber at the vertex and in which box is also placed an emission filter (7) interposed between
35 the sample chamber and said rotatable plane polarizing means, wherein said emission filter will allow only a narrow range of wavelengths of light to pass and in

which box is further mounted detection means (11) for the collection and quantitation of the amount of light which passes through said rotatable polarizing means from said sample chamber to said detecting means.

5 Optionally interposed between the light source and the excitation lens is a monochromator (2) for selected particular wavelengths of light to be trained upon the sample chamber. Interposed between said emission polarizer and said detection means is an emission lens

10 (9) for focussing the light emerging from said sample chamber upon said detection means and also an emission shutter (10) for controlling the entry of light into said detection means. Optionally interposed between said illumination means and said sample compartment is

15 an excitation shutter (13 in Figure 8) for controlling entry of light into the sample compartment. Other components of the machine are separately contained (12), including motors for rotating the emission polarizer, and electronic devices and motors for controlling the

20 shutter and monochromator, and electronic devices for data processing.

It can be easily understood by reference to figures 6 and 8 that when the light source is a laser, an excitation polarizer is not required, as laser light is

25 intrinsically polarized. Similarly, the nature of laser light makes the excitation collimating and focussing lenses unnecessary.

The fluorescent label can be covalently bound to a macromolecule by any of the many techniques commonly

30 known in the art. Oligonucleotide probes can be labelled either along their backbone, at a position in the organic bases, or at either end. End-labelling of oligonucleotides with the fluorophore can be accomplished by chemically coupling an N-

35 hydroxysuccinimide ester of the fluorophore to a 5'-amino group of the oligonucleotide which is produced during the synthesis of the oligonucleotide, or by using

a phosphoramidite reagent derivatized with the fluorophore in the synthesis of the oligonucleotide. An oligonucleotide can also be labelled at the 3' end by tagging it with fluorescently labelled nucleotides using
5 terminal transferase.

It is expected that the invention will be useful in the analysis of proteins, oligonucleotides, DNA, RNA and other macromolecules either biological or synthetic. Since the technique described in the present invention
10 is performed in the solution phase, it is particularly useful in identifying those parameters of the solution which promote or interfere with complex formation between polynucleotides and other macromolecules, for instance, pH, salt concentration or the presence of co-
15 factors. The sensitivity of the presently described technique is such that complex formation can be analyzed at concentrations of the macromolecules of less than 1 μ M. The assay can easily be performed at macromolecule concentrations of 1 nM and can be done at concentrations
20 ranging from 10 to 100 pM.

Oligonucleotides labeled with a wide range of fluorophores, including but not limited to fluorescein, eosin and coumarin may be used as probes. The identity of the fluorophore does not define the invention. The
25 present invention encompasses any determination of the presence, character or amount of a macromolecule or any determination of specific intermolecular chemical parameters or constants in which measurement of the fluorescence polarization of a fluorescently labeled
30 oligonucleotide is employed.

The invention being thus described, preferred embodiments of the invention are set forth in the Examples below. These examples are meant only to be illustrative of the invention without being limiting of
35 its scope.

Example 1: Use of fluorescence anisotropy measurements to assay protein-nucleic acid interactions.

Fluorescence polarization of a fluorescently modified oligonucleotide has been used to study the complex
5 between an oligonucleotide and a protein. This was the case for the study of the interaction of Klenow fragment with a primer labeled with 5-dimethylamino-naphthalene-1-sulfonamide (12). However the goal of these studies was to gain specific structural
10 information about the complex. Due to the choice of the fluorophore and the instrumentation used in the study, the sensitivity of this assay was approximately 10 μ M, 100,000 times less sensitive than the detection limit of the present invention. In fact, in those studies the
15 authors were unable to quantitate reliably the strength of the interaction between the protein and the oligonucleotide because the concentrations required for detection were at least 10,000 times greater than the value of the dissociation constant between the species.

20 The polarization of fluorescence of 7-dimethylamino-3-(4'-maleimidylphenyl)-4-methylcoumarin covalently bound to a 32 base pair double-stranded oligodeoxynucleotide containing the lac promoter sequence was used to monitor the formation of a complex
25 between the cAMP receptor protein and the lac promoter sequence (13). The concentration limit of the detection in this particular assay (10 nM) was several orders of magnitude above the interaction energy. It is also 1000-fold greater than the sensitivity of the assay
30 described in this invention, which can detect analytes at picomolar concentrations.

The methodology of the present invention is based upon the observation of changes in the anisotropy or polarization of fluorescence of a fluorescent probe
35 bound to a single or double-stranded oligonucleotide upon its interaction with a protein or other macromolecule. In the first set of experiments,

monitoring protein-DNA interactions, the oligodeoxyribonucleotide was a 25 mer which was labeled on the 5'-end of the sense strand with fluorescein, using a fluorescein-labeled phosphoramidite reagent in
5 automated DNA synthesis. The oligodeoxyribonucleotide was obtained commercially. The sequence of the sense strand was as follows (F = fluorescein):

5'-F-CTTGCACTAGTTAACTAGTCAGCAA-3'

The central CTAGAATTCTAG sequence is the specific
10 operator binding site of the tryptophan repressor protein, which in the presence of its co-repressor tryptophan, binds with high affinity (0.5 nM as determined by gel retardation assays, Carey, 1988) to the target sequence. Thus, the protein used in these
15 studies is the tryptophan repressor which was over-expressed and purified using the method of Paluh and Yanofsky (9), with modifications by Chou et al. (10).

The anti-sense strand of the double-stranded oligodeoxyribonucleotide was unlabeled. The two strands
20 were annealed by dissolution in 500 mM KCl, 10 mM phosphate, 0.1 mM EDTA, pH 7.0 for final concentrations near 10-100 μ M. Equimolar mixtures of the two strands as estimated from the optical density at 260 nm and the sequence of the strands were prepared and were heated to
25 85°C for 10 minutes and allowed to cool slowly at room temperature.

The fluorescein-labeled double stranded oligodeoxyribonucleotide was diluted to its final concentration, usually 0.2 nM, in a total volume of 700
30 μ l, directly into a reduced volume, 1.2 ml, fused silica cuvette. The assay buffer used for the dilution, 10 mM potassium phosphate, 0.1 mM EDTA, pH 7.6 also contained 10% glycerol and in some cases 0.4 mM L-tryptophan. Upon dilution, the KCl concentration decreased to well
35 below 1 mM. The solution was allowed to equilibrate 5

minutes before each polarization measurement.

The fluorescence polarization or anisotropy was measured in L-format using an ISS KOALA™ automated fluorometer or in T-format using our original sample
5 holder and polarizer arrangement for the ultrahigh sensitivity determinations. The exciting light was set at 488 nm and emission was monitored through a Y520 long pass filter from Hoya optics. The background
10 fluorescence from the buffer, which is non-negligible at concentrations below 10 nM was subtracted by sequential measurement of the parallel and perpendicular components of the sample and the buffer in a matched cuvette.

Sensitivity and accuracy of the measurements.

The assay was performed by sequential addition of
15 the protein in extremely small aliquots (2 μ l) in order that the total concentration of the oligodeoxyribonucleotide not decrease by more than 10%, upon the change in volume. The plots in Figures 1A and 1B show that upon sequential addition of the protein to
20 the solution containing the fluorescein-labeled oligodeoxyribonucleotide and 0.4 mM L-tryptophan, the anisotropy of the fluorescence increases in a sigmoidal fashion, when plotted against the logarithm of the protein concentration expressed as dimer. Each
25 measurement was repeated 4 times and the results were averaged. The error on each measurement was +/- 0.002 polarization units. It can be seen that even when only 10% of the oligodeoxyribonucleotide, that is 20 pM, is bound by protein, the change in the anisotropy value is
30 well beyond the error in the measurements.

We show in Figure 1A that subnanomolar quantities of oligodeoxyribonucleotide can be detected and its binding to protein produces a signal change which is 15-fold greater than the error of the measurement.

Example 2: Use of fluorescence anisotropy measurements to evaluate thermodynamic models of protein-nucleic acid interaction.

These data were analyzed in terms of two thermodynamic models, which are depicted in Figure 1C and 1D. The first (1C) is a simple protein-DNA binding model where the only species are the free protein, the free DNA and the protein-DNA complex. In the second model (Figure 1D), a monomer-dimer equilibrium is superimposed upon the protein-DNA binding equilibrium. The fits of the data using these two models and the numerical equilibrium analysis program, BIOEQS, (20) are shown in Figures 1A and 1B. The dissociation constant for the tryptophan repressor dimer-DNA interaction as obtained using the simple binding model was found to be 0.83 nM. The fit of the data using the linked equilibria model yielded a dimer-DNA dissociation constant of 0.23 nM and a dimer-monomer dissociation constant of 3.5 nM. The quality of the data is sufficient to rule out the simple binding model; the fit is of much higher quality in the case of the linked equilibria (c.f., Figure 1A and 1B). Rigorous confidence level testing reveals a steep χ^2 well for the dimer-DNA affinity, with 67% limits at ± 0.3 kcal (Figure 2). Thus, not only can complex formation at low concentration be detected, but the quality of the data is sufficient that the affinity can be determined from the fit of the data, and the efficient evaluation of alternative thermodynamic models can be made.

Example 3: Use of fluorescence anisotropy measurements in the analysis of multi-component systems in solution.

The effect of changing the concentration of the DNA oligonucleotide and of titrating the protein to the concentrations found in vivo (near 1 μ M) is shown in Figure 3. It can be seen that complexes of higher molecular weight and thus higher anisotropy are favored

at these higher concentrations of protein and DNA. Since this is a solution-based assay, the concentrations of any of the components can be varied easily. Thus, in Figure 4, one can see the effect of omitting the L-tryptophan from the assay buffer. Using 20 nM oligodeoxyribonucleotide, binding is only observed at protein concentrations above approximately 1 μ M in repressor protein dimer in the absence of tryptophan co-repressor.

10 We have thus demonstrated that these assays can be used to test quantitatively the effects of specific ligands or other drugs on formation of complexes between proteins and nucleic acids.

The results shown in Figures 1 to 4 clearly demonstrate that the polarization or anisotropy of fluorescence of fluorescently labeled oligodeoxyribonucleotides can be used to detect with high sensitivity and accuracy the interaction of the oligodeoxyribonucleotide with proteins and other large biological molecules. The fluorescence signal of fluorescein has been detected at concentrations as low as 10 pM in a total volume of 500 μ l. One femtomole of a particular DNA binding protein is easily detected, using 10 femtomoles of the fluorescently labeled target sequence, given that binding of 10% of the oligonucleotide results in a signal change that can be measured accurately. High sensitivity and data quality provide a means for the detection of complex formation and also for the extremely accurate determination of the energetic strength of the interaction, as well as the discrimination between thermodynamic binding models. The assay is quite rapid, taking only 5-10 minutes per point. It is solution based, such that the effects of small ligands and drugs, pH, salt, temperature, and other solution conditions can be evaluated easily. For example, it would require approximately 10 minutes to ascertain whether crude cell extract or an in vitro

translation assay contained a protein factor which had the ability to bind to a particular DNA sequence. A complete titration curve and its analysis requires approximately 45 minutes. Its ease of use, solution-based nature and rapidity make this assay a significant improvement over methods based on electrophoresis or filter-binding. This assay may be applied widely in the study of transcription factors and in the role of drugs and other small molecules in regulating genetic expression. Additional applications include clinically oriented tests for assaying function of transcription factors or other DNA binding proteins.

Example 4: Use of Fluorescence anisotropy measurements to assay interactions between nucleic acids.

The binding of a single-stranded oligonucleotide to another complementary single stranded DNA or RNA oligonucleotide can also be detected using this methodology. Demonstration of significant changes in anisotropy of fluorescence were made using the 5'-fluorescein labeled self-complementary 20 mer oligodeoxyribonucleotide,

5'-F-CGAACTAGTTAACTAGTACG - 3'

(F indicates fluorescein). The change in anisotropy occurs upon conversion of the denatured single-stranded oligodeoxyribonucleotide to double-stranded form by the formation of a double-stranded complex with itself. Three tests were conducted. In each, two samples were compared. Each of the two samples contained labeled oligodeoxyribonucleotide in 500 μ l of 10 mM KPO_4 , 0.1 mM EDTA, pH 7.6 at a concentration of 50 nM. One of the two samples (high salt) contained in addition 1M KCl. The high salt sample was heated to 95°C and cooled to room temperature. The heating and cooling at high salt results in conversion of largely single-stranded

oligodeoxyribonucleotide into double-stranded form. This change in form should result in reduced Brownian motion with a consequent increase in anisotropy. Fluorescence anisotropy measurements were made on each pair of samples. The results of these measurements, given in Table I, demonstrate an increase in fluorescence anisotropy of at least 20-fold over the error in the measurement upon formation of the double-stranded complex.

10

Table I

DETECTION OF OLIGONUCLEOTIDE HYBRIDIZATION
IN SOLUTION

15	Test Number	Anisotropy Low salt, before heating	Anisotropy High salt, after heating
	1	0.046 +/- 0.001	0.067 +/- 0.000
	2	0.042 +/- 0.001	0.065 +/- 0.000
	3	0.044 +/- 0.001	0.066 +/- 0.001

The change would have been much larger if the oligonucleotide had been 8-10 bases long, or if the target sequence had been single-stranded plasmid DNA, as is also typically used in hybridization assays. Thus, the detection of the formation of the double-stranded 20 mer is well below the size differential typically involved when a small oligonucleotide binds to a large single-stranded DNA molecule.

The assay based on measurement of nucleic acid interactions has application in genetic mapping and in the clinical determination of the existence of specific mutations. It may also be used in the evaluation of translation inhibition by anti-sense DNA/RNA nucleic acids, a technique with potential applications in clinical diagnostics, therapeutics, or other biomedical areas. The fluorescence anisotropy measurements

described herein are completely solution-based (i.e., require no solid support), a feature that will simplify automation of the assay. In conclusion, this invention represents a fast, accurate, reproducible, simple
5 quantitative assay for the interactions of nucleic acids with other macromolecules.

Example 6: Clinical assay for function of a DNA-binding protein in a tissue biopsy

The method of the present invention is expected to
10 find use in a clinical setting. Estrogen receptor is a DNA-binding protein, the dysfunction of which has been implicated in the etiology of breast cancer. Described herein is a method which could be employed to assay for functional estrogen receptor in biopsies from breast
15 tissue.

A cell extract will be prepared from the biopsied tissue by gentle homogenization and centrifugation as described by Flanagan et al. (19). A double-stranded oligodeoxyribonucleotide which forms a consensus
20 estrogen response element (ERE) can be prepared by automated synthesis of a pair of oligonucleotides. A preferred sequence for the sense strand is

5'-F-GGTCAGTGTGACC-3'

wherein the fluorophore (F) is incorporated by use of
25 fluorescently-labelled phosphoramidite linker in the final nucleotide addition step of the synthesis. This oligonucleotide is self-complementary. Annealing of the oligonucleotide in solution provides a double-stranded oligonucleotide labelled with a fluorophore at each 5'
30 end (*ERE).

The buffer for conducting the fluorescence polarization measurements is 10% glycerol, 80 mM KCl, pH 7.9 containing 0.2 mM EDTA. Measurements are made at room temperature.

35 Preliminary measurements are made of the fluorescence intensity of the cell extract containing no

ERE oligonucleotide (background). These values are subtracted from the measurements used in determining the emission polarization of those samples which contain cell extract. Preliminary measurements are also made of
5 the fluorescence polarization of the *ERE oligodeoxyribonucleotide in a solution free of the cell extract. Then aliquots of the cell extract are mixed with 1 pM of the *ERE oligodeoxyribonucleotide and the fluorescence polarization is again measured. Comparison
10 of the polarization values obtained in the presence of cell extract with the value of the free *ERE provides a measure of the binding function of estrogen receptor present in the sample.

As a control experiment, results using a sample
15 cell extract prepared from cells known to contain functional estrogen receptor should be obtained and compared with the results from the extract prepared from the clinical sample.

To most clearly describe the experiment, an example
20 of sample formulations is provided in Table II.

Table II
SAMPLE FORMULATIONS FOR DETERMINING BINDING
OF ERE TO ESTROGEN RECEPTOR
IN A CLINICAL SAMPLE

5	Biopsy				Background		
	<u>[ERE]</u>	<u>*ERE</u>	<u>Extract</u>	<u>Buffer</u>	<u>*ERE</u>	<u>Extract</u>	<u>Buffer</u>
	1pM	5 ^a	0	995	0	0	1000
	1pM	5	100	895	0	100	900
	1pM	5	250	745	0	250	750
10	1pM	5	500	455	0	500	500
	1pM	5	950	45	0	950	50
15	Control				Background		
	<u>[ERE]</u>	<u>*ERE</u>	<u>Extract</u>	<u>Buffer</u>	<u>*ERE</u>	<u>Extract</u>	<u>Buffer</u>
	1pM	5	0	995	0	0	1000
	1pM	5	100	895	0	100	900
	1pM	5	250	745	0	250	750
	1pM	5	500	455	0	500	500
	1pM	5	950	45	0	950	50

^a All amounts are in μ l.

20 To quantitate the amount of estrogen receptor in the sample, the cell extract can be titrated with various amounts of labelled *ERE and the result compared with a standard curves obtained using known amounts of purified estrogen receptor and *ERE.

25 **Example 7: Clinical assay for a specific point mutation in a gene by oligonucleotide hybridization to mRNA from a tissue biopsy**

Specific mutations in the cholesterol receptor gene

have been found to lead to hypercholesterolemia, a condition which leads to early death of the patient due to arterial disease if measures are not taken to control cholesterol levels in the circulation. It is expected
5 that early detection of the condition by neonatal or prenatal genetic testing, and thus early intervention would provide for a better prognosis for afflicted individuals. Accordingly, in this example, a method for detecting mutations in the cholesterol receptor gene by
10 assay of mRNA for binding to oligonucleotide probes is described. This method is of course generalizable to the detection of other mutations.

8-10 base oligonucleotides, labelled on the 5' end by methods known in the art, are designed to be
15 complementary to those portions of the mRNA transcript of the wild type cholesterol receptor gene which have been previously shown to be mutated in patients having familial hypercholesterolemia. Each oligonucleotide is designed to provide a similar decrease in T_m (the melting
20 temperature of a duplex between the oligo and a hybridized complementary strand) upon binding to a sequence that is entirely complementary, with the exception of a single mismatched base pair, by varying its length and GC-content. An experiment is conducted
25 to determine the temperature at which the wild type mRNA remains mostly hybridized to each oligonucleotide, but mRNA obtained from a liver biopsy of a panel of patients which present the mutations observed to cause hypercholesterolemia is not hybridized by the
30 oligonucleotide complementary to the wild type sequence in the mutated region.

100 mg of tissue generally yields approximately 1 pmole of a specific 1 kilobase mRNA. In a volume of 1 ml, this would correspond to 1 nM of specific mRNA. For
35 a 1:1 hybridization, 1 nM fluorescently labelled oligonucleotide would be used. This sample size provides a readily detected signal; thus smaller samples

could be used. The fluorescence polarization of the oligonucleotide alone, mixed with wild-type mRNA at 1 nM and mixed with mRNA from the clinical sample at approximately 1 nM are each determined at the temperature found in the initial experiment to provide the maximal difference in binding of the oligonucleotide to the wild-type and the mutant mRNA sequence. It would be observed that tissue containing the wild-type mRNA would show a polarization greater than that observed for the oligonucleotide alone, while tissue containing mutant mRNA would show a polarization equal to that of the oligonucleotide alone.

As a control experiment, the fluorescence emission of the mRNA preparation in the absence of labelled oligonucleotide is determined in each plane of emission polarization. These background values are subtracted from each measurement made in the hybridization experiments.

Example 8: Apparatus for conducting fluorescence polarization measurements with high sensitivity

The diagram shown in Figure 5 shows modifications made to an ISS KoalaTM fluorometer to produce an instrument having the sensitivity required to implement the present invention. The modifications include (1) reducing the light path from 30 cm to 20 cm; (2) positioning the emission lens to within 1 cm of the sample holder; and (3) replacing the Glan Thompson polarizers with UV grade film polarizers mounted directly on the sample holder. These improvements increase the instrument sensitivity dramatically. In the tests done to demonstrate the increase in sensitivity achieved by these modifications, a fluorescently labeled 25 mer oligonucleotide with the following sequence was used.

5'-F-ATCGAACTAGTTAACTAGTACGCAA-3'

As shown in Table III, we were able to detect oligonucleotide at a concentration of 9 pM in 500 μ l using a Xenon arc lamp excitation source rather than the argon ion source indicated in the drawing. This represents an increase in sensitivity of 10-fold as compared to the unmodified instrument. Given that we can detect a 10% change in the polarization, we can therefore detect 0.9 pM of protein or nucleic acid or synthetic polymer in solution. This level of sensitivity corresponds to 450 attomoles of macromolecule.

Table III

SENSITIVITY LIMIT ASSAY

USING MODIFIED FLUOROMETER AND SAMPLE CELL

<u>Solution</u>	<u>Intensity (Counts)</u>
9 pM F-25 mer	1967.8 +/- 1.2
Buffer background	243.9 +/- 0.4

Sensitivity of the modified instrument could be improved by two further modifications. (1) Including a sharp bandpass excitation filter would increase sensitivity by a factor of 10-fold. (2) Substitution of an argon ion laser light source for the Xenon arc lamp used in the test reported herein would increase sensitivity by an additional 100-fold due to the increased intensity of the excitation beam and its monochromatic and polarized nature. Since we are background limited and the monochromators in the basic ISS instrument are not good at stray light rejection, most of the background intensity results from scattered exciting light. With a laser, there is only 488 nm light, and thus no stray light of other wavelengths will enter the sample. Secondly, laser light is plane polarized, eliminating the need for an excitation polarizer. Finally, fluorescence intensity is directly proportional to the excitation source intensity, and a

laser, even a small one, would provide more power than the Xenon arc lamp. In the modified design, dilution with concomitant increase in gain did not increase sensitivity, since use of a lamp excitation source
5 caused the detection level to be background-limited rather than noise-limited. Thus, another factor of 10 increase in sensitivity is available if the stray exciting light can be eliminated.

The invention being thus described, various
10 modifications of the materials and methods set forth in the description will be obvious to a practitioner of the invention who is skilled in the art. Such variations upon the invention described are to be considered within the scope of the invention as claimed below.

15 REFERENCES

The following references are cited in the disclosure. Each of the references below is hereby incorporated in its entirety by such citation.

US Patents

- | | | | | | |
|----|----|-----------|---------|----|-----------------------------------|
| 20 | 1. | 4,269,511 | 5/1981 | to | Erwin |
| | 2. | 4,516,856 | 5/1985 | to | Popelka |
| | 3. | 4,585,862 | 4/1986 | to | Wang, C-H, et al. |
| | 4. | 4,668,640 | 5/1987 | to | Wang, C-H, et al. |
| | 5. | 4,784,961 | 11/1988 | to | Russell |
| 25 | 6. | 4,902,630 | 2/1990 | to | Bennet, L.G. and
Chiapetta, G. |
| | 7. | 4,952,691 | 8/1990 | to | Wang et al. |
| | 8. | 5,066,426 | 11/1991 | to | Wang, et al. |

Other references

- | | | |
|----|-----|---|
| 30 | 9. | Paluh, J.L. and Yanofsky, C. (1983) Nucl. Acids Res. |
| | | 14, 7851-60 |
| | 10. | Chou, W-Y., Buber, C., and Matthews K.S. (1989) J. |
| | | Biol Chem. <u>264</u> 18309-13 |
| | 11. | Carey, J., (1988) Proc. Natl. Acad. Sci <u>85</u> , 975-9 |

12. Guest, C.R., Hochstrasser, R.A., Dupuy, C.G., Allen, D.J., Benkovic, S.J., and Miller D. P. (1991) *Biochemistry* 30, 8759-70.
13. Heyduk, T. and Lee, J.C. (1990) *Proc. Natl. Acad. Sci.* 87 1744-8
14. Beecham, J.M., (1992) *Methods in Enzymology* Vol 210, pg. 37-53.
15. Urios, P and Cittanova, N. (1990) *Anal. Bioc.* 185 308-12
- 10 16. Giedroc, D.P., Khan, R., and Barnhart, K. (1991) *Biochem.* 30 8230-42
17. Murakami, A., Nakaura, M., Nakatsuji, Y., Nagahara, S., Tran-Cong, Q., and 18. Makino, K. (1991) *Nucl. Acids Res.* 19 4907-4912.
- 15 19. P.M. Flanagan et al. (1992) *Proc. Natl. Acad. Sci. USA* 89:7659-7663..
20. C.A. Royer et al. (1990) *Anal. Biochem.* 191:287-294

CLAIMS

What is claimed is:

- 1 1. A method for measuring the binding of a
2 polynucleotide to a macromolecule to form a non-covalent
3 complex which comprises:
 - 4 i) labelling said polynucleotide with a fluorescent
5 label;
 - 6 ii) obtaining a first measurement of the
7 polarization of the fluorescent emission from said
8 label;
 - 9 iii) contacting said labelled polynucleotide with
10 said macromolecule, under conditions favorable to
11 binding of said labelled polynucleotide to said
12 macromolecule;
 - 13 iv) obtaining a second measurement of the
14 polarization of the fluorescent emission from said label
15 under said conditions favorable to binding; and
16 v) comparing said first measurement with said
17 second measurement.
- 1 2. A method as recited in claim 1, wherein said
2 label is fluorescein.
- 1 3. A method as recited in claim 1, wherein said
2 polynucleotide is a single-stranded
3 oligodeoxyribonucleotide of length less than or equal to
4 40 bases.

1 4. A method as recited in claim 1, wherein said
2 polynucleotide is a double-stranded
3 oligodeoxyribonucleotide of length less than or equal to
4 40 basepairs.

1 5. A method as recited in claim 1, wherein said
2 macromolecule is a protein.

1 6. A method as recited in claim 3, wherein said
2 macromolecule is a second polynucleotide.

1 7. A method as recited in claim 1, wherein said
2 polynucleotide is present at a concentration of less
3 than or equal to 1 nanomolar.

1 8. A method as recited in claim 7, wherein said
2 macromolecule is present at a concentration of less than
3 or equal to 1 nanomolar.

1 9. A method for diagnosing a genetic mutation
2 which comprises:
3 i) obtaining a sample of DNA from a patient;
4 ii) obtaining a first measurement of the
5 polarization of the fluorescent emission from a
6 fluorescently-labelled oligonucleotide;
7 iii) contacting said fluorescently-labelled
8 oligonucleotide with said DNA under conditions favorable
9 to binding of said fluorescently-labelled
10 oligonucleotide to said DNA;
11 iv) obtaining a second measurement of the
12 polarization of the fluorescent emission from said
13 fluorescently-labelled oligonucleotide under said
14 conditions favorable to binding; and
15 v) comparing said second measurement to said first
16 measurement.

1 10. A method for diagnosing variation in the
2 amount or nature of a DNA binding protein which
3 comprises:
4 i) fluorescently labelling an oligonucleotide
5 having the nucleotide sequence recognized by a DNA-
6 binding protein, wherein said oligonucleotide may be
7 either double-stranded or single stranded.
8 ii) obtaining a sample containing the DNA-binding
9 protein to be tested;
10 iii) obtaining a first measurement of the
11 polarization of the fluorescent emission from said
12 fluorescently-labelled oligonucleotide;
13 iv) contacting said fluorescently-labelled
14 oligonucleotide with said sample under conditions
15 favorable to binding of said fluorescently-labelled
16 polynucleotide to said DNA-binding protein;
17 v) obtaining a second measurement of the
18 polarization of the fluorescent emission from said
19 fluorescently-labelled oligonucleotide under said
20 conditions favorable to binding; and
21 vi) comparing said second measurement to said first
22 measurement.

1 11. The method of claim 8, which further
2 comprises:
3 vii) adding a second aliquot of unlabelled
4 polynucleotide having the same nucleotide sequence as
5 said labelled polynucleotide;
6 viii) obtaining a third measurement of the
7 polarization of the fluorescent emission from said
8 fluorescently-labelled oligonucleotide under said
9 conditions favorable to binding; and
10 vi) comparing said measurement to said first and
11 second measurements.

1 12. An apparatus for measuring the polarization of
2 fluorescent emission which comprises:
3 a box for the exclusion of light, in which is
4 placed;
5 an excitation means for producing polarized light
6 having a narrow range of wavelengths;
7 a sample chamber illuminated by said polarized
8 light;
9 emission polarizers for imposing polarization upon
10 fluorescence emission from said sample chamber, wherein
11 said emission polarizers are of a film type;
12 detection means for detecting said fluorescence
13 emission; and
14 emission lenses for focussing said fluorescent
15 emission upon said detection means.

1 13. An apparatus for measuring the polarization of
2 fluorescent emission which comprises:
3 a box for the exclusion of light in which is placed
4 an illumination means so as to illuminate a sample
5 chamber, through a collimating lens and a focusing lens,
6 and further through a first polarizing means for plane
7 polarizing the light from said illumination means, said
8 lenses and first polarizing means, being mounted in a
9 line connecting said illumination means and said sample
10 chamber, and further said sample chamber being mounted
11 between two additional polarizing means, said polarizing
12 means being placed so that the line between them and
13 including said sample chamber is perpendicular to the
14 light path from said illumination means to said sample
15 chamber, said polarizing means being mounted so that the
16 plane of polarization of the second of said polarizing
17 means is parallel to the plane of polarization of said
18 first polarizing means and also so that the plane of
19 polarization of said second polarizing means is
20 perpendicular to the plane of polarization of the third
21 of said polarizing means and in which box is also placed

22 detection means for the collection and quantitation of
23 the amount of light which passes through said polarizing
24 means from said sample chamber to said detecting means.

1 14. The apparatus of claim 12, wherein said
2 illumination means is a xenon arc lamp.

1 15. The apparatus of claim 13, wherein said
2 collimating lens and said focusing lens are substituted
3 by a fiber optic cable.

1 16. The apparatus of claim 13, wherein said
2 illumination means is a laser and each of said
3 collimating lens, said focusing lens and said first
4 polarizing means are not present.

1 17. The apparatus of claim 16, wherein said laser
2 is a tunable dye laser or a solid state laser.

1 18. The apparatus of claim 13, wherein each of
2 said polarizing means are ultraviolet grade film
3 polarizers.

1 19. The apparatus of claim 16, wherein each of
2 said polarizing means are ultraviolet grade film
3 polarizers.

1 20. The apparatus of claim 13, wherein the length
2 of the light path from said illumination means to said
3 detection means is 20 centimeters or less.

1 21. The apparatus of claim 16, wherein the light
2 from said illumination means is conducted to said sample
3 chamber by a glass fiber.

1 22. An apparatus for measuring the polarization of
2 fluorescent emission which comprises:

3 A box for the exclusion of light in which is placed
4 an illumination means so as to illuminate a sample
5 chamber through an excitation lens and further through
6 an excitation filter, wherein said excitation filter
7 passes only a narrow range of wavelengths of light, and
8 further through a fixed means of plane polarizing light
9 which shines on said sample chamber, such that each of
10 these elements are mounted in the light path from said
11 illuminating means to said sample chamber, said sample
12 chamber being mounted relative to a rotatable polarizing
13 means, which plane polarizes light which passes through
14 said rotatable plane polarizing means, so that a path
15 from said illumination means through said sample chamber
16 to said rotatable polarizing means forms a right angle
17 with the sample chamber at the vertex and in which box
18 is also placed an emission filter interposed between the
19 sample chamber and said rotatable plane polarizing
20 means, wherein said emission filter will allow only a
21 narrow range of wavelengths of light to pass and in
22 which box is further mounted detection means for the
23 collection and quantitation of the amount of light which
24 passes through said rotatable polarizing means from said
25 sample chamber to said detecting means.

1 23. The apparatus of claim 22, wherein said
2 illumination means is a laser and each of said
3 excitation lens, excitation filter and said fixed
4 polarization means are not present.

1 24. A kit for the clinical diagnosis of the amount
2 and function of a specific DNA-binding protein, which
3 comprises a fluorescently labelled oligonucleotide and
4 a container.

34

1 25. The kit of claim 24, wherein said
2 oligonucleotide has the sequence
3 5'-GGTCACTGTGACC-3'

AMENDED CLAIMS

[received by the International Bureau on 19 April 1994 (19.04.94);
original claims 1-25 replaced by amended claims 1-30 (11 pages)]

What is claimed is:

- 1 1. A method for measuring the binding of a
2 polynucleotide to a macromolecule to form a complex
3 which comprises:
 - 4 i) labelling said polynucleotide with a fluorescent
5 label;
 - 6 ii) obtaining a first measurement of the
7 polarization of the fluorescent emission from said
8 label;
 - 9 iii) contacting said labelled polynucleotide with
10 said macromolecule, under conditions favorable to
11 binding of said polynucleotide to said macromolecule and
12 such that the concentration of said labelled
13 polynucleotide is less than or equal to 5 nanomolar;
 - 14 iv) obtaining a second measurement of the
15 polarization of the fluorescent emission from said
16 label; and
 - 17 v) comparing said first measurement with said
18 second measurement.
- 1 2. A method as recited in claim 1, wherein said
2 label is fluorescein.
- 1 3. A method as recited in claim 1, wherein said
2 polynucleotide is a single-stranded
3 oligodeoxyribonucleotide of length less than or equal to
4 40 bases.

1 4. A method as recited in claim 1, wherein said
2 polynucleotide is a double-stranded
3 oligodeoxyribonucleotide of length less than or equal to
4 40 basepairs.

1 5. A method as recited in claim 1, wherein said
2 macromolecule is a protein.

1 6. A method as recited in claim 3, wherein said
2 macromolecule is a second polynucleotide.

1 7. A method as recited in claim 1, wherein said
2 macromolecule is present at a concentration of less than
3 or equal to 1 nanomolar.

1 8. A method for diagnosing a genetic mutation
2 which comprises:
3 i) obtaining a sample of DNA from a patient;
4 ii) obtaining a first measurement of the
5 polarization of the fluorescent emission from a
6 fluorescently-labelled oligonucleotide;
7 iii) contacting said fluorescently-labelled
8 oligonucleotide with said DNA under conditions such that
9 the concentration of said fluorescently-labelled
10 oligonucleotide is less than 5 nanomolar;
11 iv) obtaining a second measurement of the
12 polarization of the fluorescent emission from said
13 fluorescently-labelled oligonucleotide; and
14 v) comparing said second measurement to said first
15 measurement.

1 9. A method for diagnosing variation in the amount
2 or nature of a DNA binding protein which comprises:

3 i) fluorescently labelling an oligonucleotide
4 having the nucleotide sequence recognized by a DNA-
5 binding protein, wherein said oligonucleotide may be
6 either double-stranded or single stranded.

7 ii) obtaining a sample containing the DNA-binding
8 protein to be tested;

9 iii) obtaining a first measurement of the
10 polarization of the fluorescent emission from said
11 fluorescently-labelled oligonucleotide;

12 iv) contacting said fluorescently-labelled
13 oligonucleotide with said sample under conditions such
14 that the concentration of said fluorescently-labelled
15 polynucleotide is less than 5 nanomolar;

16 v) obtaining a second measurement of the
17 polarization of the fluorescent emission from said
18 fluorescently-labelled oligonucleotide;

19 vi) comparing said second measurement to said first
20 measurement; and

21 vii) diagnosing a variation in the amount or nature
22 of said DNA binding protein by observing a change in the
23 polarization measured in step (iii) compared to the
24 polarization measured in step (vi).

1 10. The method of claim 7, which further
2 comprises:

3 vii) adding a second aliquot of unlabelled
4 polynucleotide having the same nucleotide sequence as
5 said labelled polynucleotide;

6 viii) obtaining a third measurement of the
7 polarization of the fluorescent emission from said
8 fluorescently-labelled oligonucleotide under said
9 conditions favorable to binding; and

10 vi) comparing said measurement to said first and
11 second measurements.

1 11. An apparatus for measuring the polarization of
2 fluorescent emission which comprises:
3 a box for the exclusion of light, in which is
4 placed;
5 an excitation means for producing polarized light
6 having a narrow range of wavelengths;
7 a sample chamber illuminated by said polarized
8 light;
9 emission polarizers for imposing polarization upon
10 fluorescence emission from said sample chamber, wherein
11 said emission polarizers are of a film type;
12 detection means for detecting said fluorescence
13 emission; and
14 emission lenses for focussing said fluorescent
15 emission upon said detection means.

1 12. An apparatus for measuring the polarization of
2 fluorescent emission which comprises:
3 a box for the exclusion of light in which is placed
4 an illumination means so as to illuminate a sample
5 chamber, through a collimating lens and a focusing lens,
6 and further through a first polarizing means for plane
7 polarizing the light from said illumination means, said
8 lenses and first polarizing means, being mounted in a
9 line connecting said illumination means and said sample
10 chamber, and further said sample chamber being mounted
11 between two additional polarizing means, said polarizing
12 means being placed so that the line between them and
13 including said sample chamber is perpendicular to the
14 light path from said illumination means to said sample
15 chamber, said polarizing means being mounted so that the
16 plane of polarization of the second of said polarizing
17 means is parallel to the plane of polarization of said
18 first polarizing means and also so that the plane of
19 polarization of said second polarizing means is
20 perpendicular to the plane of polarization of the third
21 of said polarizing means and in which box is also placed

22 detection means for the collection and quantitation of
23 the amount of light which passes through said polarizing
24 means from said sample chamber to said detecting means.

1 13. The apparatus of claim 11, wherein said
2 illumination means is a xenon arc lamp.

1 14. The apparatus of claim 11, wherein said
2 collimating lens and said focusing lens are substituted
3 by a fiber optic cable.

1 15. The apparatus of claim 12, wherein said
2 illumination means is a laser and each of said
3 collimating lens, said focusing lens and said first
4 polarizing means are not present.

1 16. The apparatus of claim 15, wherein said laser
2 is a tunable dye laser or a solid state laser.

1 17. The apparatus of claim 12, wherein each of
2 said polarizing means are ultraviolet grade film
3 polarizers.

1 18. The apparatus of claim 15, wherein each of
2 said polarizing means are ultraviolet grade film
3 polarizers.

1 19. The apparatus of claim 12, wherein the length
2 of the light path from said illumination means to said
3 detection means is 20 centimeters or less.

1 20. The apparatus of claim 15, wherein the light
2 from said illumination means is conducted to said sample
3 chamber by a glass fiber.

1 21. An apparatus for measuring the polarization of
2 fluorescent emission which comprises:

3 A box for the exclusion of light in which is placed
4 an illumination means so as to illuminate a sample
5 chamber through an excitation lens and further through
6 an excitation filter, wherein said excitation filter
7 passes only a narrow range of wavelengths of light, and
8 further through a fixed means of plane polarizing light
9 which shines on said sample chamber, such that each of
10 these elements are mounted in the light path from said
11 illuminating means to said sample chamber, said sample
12 chamber being mounted relative to a rotatable polarizing
13 means, which plane polarizes light which passes through
14 said rotatable plane polarizing means, so that a path
15 from said illumination means through said sample chamber
16 to said rotatable polarizing means forms a right angle
17 with the sample chamber at the vertex and in which box
18 is also placed an emission filter interposed between the
19 sample chamber and said rotatable plane polarizing
20 means, wherein said emission filter will allow only a
21 narrow range of wavelengths of light to pass and in
22 which box is further mounted detection means for the
23 collection and quantitation of the amount of light which
24 passes through said rotatable polarizing means from said
25 sample chamber to said detecting means.

1 22. The apparatus of claim 21, wherein said
2 illumination means is a laser and each of said
3 excitation lens, excitation filter and said fixed
4 polarization means are not present.

1 23. A kit for the clinical diagnosis of the amount
2 and function of a specific DNA-binding protein, which
3 comprises a fluorescently labelled oligonucleotide and
4 a container.

1 24. The kit of claim 23, wherein said
2 oligonucleotide has the sequence
3 5'-GGTCACTGTGACC-3'

1 25. A method for measuring the binding of a
2 polynucleotide to a macromolecule to form a complex
3 which comprises:

4 i) labelling said polynucleotide with a fluorescent
5 label;

6 ii) obtaining a first measurement of the
7 polarization of the fluorescent emission from said
8 label;

9 iii) contacting said labelled polynucleotide with
10 said macromolecule, under conditions favorable to
11 binding of said polynucleotide to said macromolecule and
12 such that the concentration of said labelled
13 polynucleotide ranges from 1 nanomolar to 10 picomolar;

14 iv) obtaining a second measurement of the
15 polarization of the fluorescent emission from said
16 label; and

17 v) comparing said first measurement with said
18 second measurement.

1 26. A method for diagnosing a genetic mutation
2 which comprises:

3 i) obtaining a sample of DNA from a patient;

4 ii) obtaining a first measurement of the
5 polarization of the fluorescent emission from a
6 fluorescently-labelled oligonucleotide;

7 iii) contacting said fluorescently-labelled
8 oligonucleotide with said DNA under conditions such that
9 the concentration of said fluorescently-labelled
10 oligonucleotide ranges from 1 nanomolar to 10 picomolar;

11 iv) obtaining a second measurement of the
12 polarization of the fluorescent emission from said
13 fluorescently-labelled oligonucleotide;

14 v). comparing said second measurement to said first

15 measurement; and

16 vi) diagnosing a genetic mutation by observing a
17 change in polarization measured in step (ii) and step
18 (iv).

1 27. A method for diagnosing variation in the
2 amount or nature of a DNA binding protein which
3 comprises:

4 i) fluorescently labelling an oligonucleotide
5 having the nucleotide sequence recognized by a DNA-
6 binding protein, wherein said oligonucleotide may be
7 either double-stranded or single stranded.

8 ii) obtaining a sample containing the DNA-binding
9 protein to be tested;

10 iii) obtaining a first measurement of the
11 polarization of the fluorescent emission from said
12 fluorescently-labelled oligonucleotide;

13 iv) contacting said fluorescently-labelled
14 oligonucleotide with said sample under conditions such
15 that the concentration of said fluorescently-labelled
16 polynucleotide ranges from 1 nanomolar to 10 picomolar;

17 v) obtaining a second measurement of the
18 polarization of the fluorescent emission from said
19 fluorescently-labelled oligonucleotide;

20 vi) comparing said second measurement to said first
21 measurement; and

22 vii) diagnosing a variation in the amount or nature
23 of said DNA binding protein by observing a change in the
24 polarization measured in step (iii) compared to the
25 polarization measured in step (vi).

1 28. A method for measuring the binding of a
2 polynucleotide to a macromolecule to form a complex
3 which comprises:

4 i) labelling said polynucleotide with a fluorescent
5 label;

6 ii) obtaining a first measurement of the
7 polarization of the fluorescent emission from said
8 label;

9 iii) contacting said labelled polynucleotide with
10 said macromolecule, under conditions favorable to
11 binding of said polynucleotide to said macromolecule and
12 such that the concentration of said labelled
13 polynucleotide ranges from 1 nanomolar to 10 picomolar;

14 iv) obtaining a second measurement of the
15 polarization of the fluorescent emission from said
16 label;

17 v) comparing said first measurement with said
18 second measurement; and

19 vi) detecting formation of said complex by
20 observing an increase in the polarization measured in
21 step (iv) compared to the polarization measured in step
22 (ii);

23 wherein said measurements of fluorescence polarization
24 are made using an apparatus having a component selected
25 from the group consisting of a UV grade film polarizer
26 mounted directly on the sample compartment, a Xenon arc
27 lamp excitation source, a Xenon arc lamp excitation
28 source coupled to the sample compartment by a fiber
29 optic cable, and a laser light source.

1 29. A method for diagnosing a genetic mutation
2 which comprises:
3 i) obtaining a sample of DNA from a patient;
4 ii) obtaining a first measurement of the
5 polarization of the fluorescent emission from a
6 fluorescently-labelled oligonucleotide;
7 iii) contacting said fluorescently-labelled
8 oligonucleotide with said DNA under conditions such that
9 the concentration of said fluorescently-labelled
10 oligonucleotide ranges from 1 nanomolar to 10 picomolar;
11 iv) obtaining a second measurement of the
12 polarization of the fluorescent emission from said
13 fluorescently-labelled oligonucleotide;
14 v) comparing said second measurement to said first
15 measurement; and
16 vi) diagnosing a genetic mutation by observing a
17 change in polarization measured in step (ii) and step
18 (iv);
19 wherein said measurements of fluorescence polarization
20 are made using an apparatus having a component selected
21 from the group consisting of a UV grade film polarizer
22 mounted directly on the sample compartment, a Xenon arc
23 lamp excitation source, a Xenon arc lamp excitation
24 source coupled to the sample compartment by a fiber
25 optic cable, and a laser light source.

1 30. A method for diagnosing variation in the
2 amount or nature of a DNA binding protein which
3 comprises:
4 i) fluorescently labelling an oligonucleotide
5 having the nucleotide sequence recognized by a DNA-
6 binding protein, wherein said oligonucleotide may be
7 either double-stranded or single stranded.
8 ii) obtaining a sample containing the DNA-binding
9 protein to be tested;
10 iii) obtaining a first measurement of the
11 polarization of the fluorescent emission from said
12 fluorescently-labelled oligonucleotide;
13 iv) contacting said fluorescently-labelled
14 oligonucleotide with said sample under conditions such
15 that the concentration of said fluorescently-labelled
16 polynucleotide ranges from 1 nanomolar to 10 picomolar;
17 v) obtaining a second measurement of the
18 polarization of the fluorescent emission from said
19 fluorescently-labelled oligonucleotide;
20 vi) comparing said second measurement to said first
21 measurement; and
22 vii) diagnosing a variation in the amount or nature
23 of said DNA binding protein by observing a change in the
24 polarization measured in step (iii) compared to the
25 polarization measured in step (vi).;
26 wherein said measurements of fluorescence polarization
27 are made using an apparatus having a component selected
28 from the group consisting of a UV grade film polarizer
29 mounted directly on the sample compartment, a Xenon arc
30 lamp excitation source, a Xenon arc lamp excitation
31 source coupled to the sample compartment by a fiber
32 optic cable, and a laser light source.

FIG. 1A




FIG. 1C




FIG. 1B





FIG. 1D

 $2M + Op$ 

SUBSTITUTE SHEET (RULE 26)

FIG. 2




FIG. 3





FIG. 4

ANISOTROPY







FIG. 5





FIG. 6

FIG. 7





FIG. 8






FIG. 9

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US93/11263

A. CLASSIFICATION OF SUBJECT MATTER

IPC(5) : C12Q 1/68; C12M 1/34; G01J 1/42

US CL : 436/6, 291; 250/372

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 436/6, 291; 250/372

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

MEDLINE, APS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Nucleic Acids Research, Vol. 19, No. 15, issued 1991, Murakami et al., "Fluorescent-labeled oligonucleotide probes: detection of hybrid formation in solution by fluorescence polarization spectroscopy," pages 4097-4102, see entire document.	1-25
Y	Proceedings of the National Academy of Sciences, Vol. 87, issued March 1990, Heyduk et al., "Application of fluorescence energy transfer and polarization to monitor <i>Escherichia coli</i> cAMP receptor protein and <i>lac</i> promoter interaction," pages 1744-1748, see entire document.	1-25

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be part of particular relevance	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A*	document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means		
P document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

07 February 1994

Date of mailing of the international search report

16 FEB 1994

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. NOT APPLICABLE

Authorized officer

SCOTT HOUTTEMAN

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORTInternational application No.
PCT/US93/11263**C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Analytical Biochemistry, Vol. 169, issued 1988, Matthews et al., "Analytical strategies for the use of DNA probes," pages 1-25, see page 19.	11

THIS PAGE BLANK (USPTO)